Skip to main content
SpringerLink
Log in

Multiple Sclerosis

  • Protocol
  • First Online:
Clinical Trials in Neurology

Part of the book series: Neuromethods ((NM,volume 138))

Abstract

Multiple sclerosis is proposed to be a neurological syndrome that may have a significant impact on patients’ functionality and quality of life. Due to the complexity of clinical trials in multiple sclerosis, conducting research studies in this field poses critical challenges to investigators. A review of the literature was conducted in the online database “Web of Science” for identifying the 100 most cited trials in multiple sclerosis. Articles published 2010 and 2015 were included. This chapter discusses the main insights that emerged from this review and presents fruitful suggestions for advancing the research scope in multiple sclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Newcombe J et al (1991) Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain 114(Pt 2):1013–1023

    Article  PubMed  Google Scholar 

  2. Filippi M, Rocca MA (2011) MR imaging of multiple sclerosis. Radiology 259(3):659–681

    Article  PubMed  Google Scholar 

  3. Rocca MA, Messina R, Filippi M (2013) Multiple sclerosis imaging: recent advances. J Neurol 260(3):929–935

    Article  PubMed  Google Scholar 

  4. Pohl D et al (2007) Paediatric multiple sclerosis and acute disseminated encephalomyelitis in Germany: results of a nationwide survey. Eur J Pediatr 166(5):405–412

    Article  PubMed  Google Scholar 

  5. Mackenzie IS et al (2014) Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry 85(1):76–84

    Article  CAS  PubMed  Google Scholar 

  6. Noonan CW et al (2010) The prevalence of multiple sclerosis in 3 US communities. Prev Chronic Dis 7(1):A12

    PubMed  Google Scholar 

  7. Kinsinger SW, Lattie E, Mohr DC (2010) Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology 24(5):573–580

    Article  PubMed  PubMed Central  Google Scholar 

  8. Noseworthy JH et al (2000) Multiple sclerosis. N Engl J Med 343(13):938–952

    Article  CAS  PubMed  Google Scholar 

  9. Montalban X (2011) Review of methodological issues of clinical trials in multiple sclerosis. J Neurol Sci 311(Suppl 1):S35–S42

    Article  PubMed  Google Scholar 

  10. Cohen JA et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402–415

    Article  CAS  PubMed  Google Scholar 

  11. Calabresi PA et al (2014) Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 13(6):545–556

    Article  CAS  PubMed  Google Scholar 

  12. Cohen JA et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828

    Article  CAS  PubMed  Google Scholar 

  13. Coles AJ et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829–1839

    Article  CAS  PubMed  Google Scholar 

  14. Confavreux C et al (2012) Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 18(9):1278–1289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Confavreux C et al (2014) Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 13(3):247–256

    Article  CAS  PubMed  Google Scholar 

  16. Fox RJ et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367(12):1087–1097

    Article  CAS  PubMed  Google Scholar 

  17. Freedman MS et al (2012) Teriflunomide added to interferon-beta in relapsing multiple sclerosis: a randomized phase II trial. Neurology 78(23):1877–1885

    Article  CAS  PubMed  Google Scholar 

  18. Ghezzi A et al (2010) Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 75(10):912–917

    Article  CAS  PubMed  Google Scholar 

  19. Gold R et al (2014) Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol 261(2):267–276

    Article  CAS  PubMed  Google Scholar 

  20. Gold R et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367(12):1098–1107

    Article  CAS  PubMed  Google Scholar 

  21. Kappos L et al (2012) Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study. Mult Scler 18(3):314–321

    Article  CAS  PubMed  Google Scholar 

  22. Kappos L et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387–401

    Article  CAS  PubMed  Google Scholar 

  23. Khatri B et al (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 10(6):520–529

    Article  CAS  PubMed  Google Scholar 

  24. MacManus DG et al (2011) BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 258(3):449–456

    Article  CAS  PubMed  Google Scholar 

  25. Mehling M et al (2011) Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients. Ann Neurol 69(2):408–413

    Article  CAS  PubMed  Google Scholar 

  26. Mellergard J et al (2010) Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 16(2):208–217

    Article  CAS  PubMed  Google Scholar 

  27. Phillips JT et al (2011) Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 17(8):970–979

    Article  PubMed  Google Scholar 

  28. O’Connor P et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365(14):1293–1303

    Article  PubMed  Google Scholar 

  29. Vermersch P et al (2014) Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 20(6):705–716

    Article  CAS  PubMed  Google Scholar 

  30. Soilu-Hanninen M et al (2012) A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 83(5):565–571

    Article  PubMed  Google Scholar 

  31. Zamboni P et al (2012) Venous angioplasty in patients with multiple sclerosis: results of a pilot study. Eur J Vasc Endovasc Surg 43(1):116–122

    Article  CAS  PubMed  Google Scholar 

  32. Khan S et al (2011) Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol 185(4):1344–1349

    Article  CAS  PubMed  Google Scholar 

  33. Putzki N et al (2010) Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries. Eur J Neurol 17(1):31–37

    Article  CAS  PubMed  Google Scholar 

  34. Calabresi PA et al (2014) Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 13(7):657–665

    Article  CAS  PubMed  Google Scholar 

  35. Bermel RA et al (2010) Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler 16(5):588–596

    Article  CAS  PubMed  Google Scholar 

  36. Goodin DS et al (2012) Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 83(3):282–287

    Article  PubMed  Google Scholar 

  37. Dorr J et al (2012) Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): study protocol for a randomized controlled trial. Trials 13:15

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Kimball S et al (2011) Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab 96(9):2826–2834

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mosayebi G et al (2011) Therapeutic effect of vitamin D3 in multiple sclerosis patients. Immunol Invest 40(6):627–639

    Article  CAS  PubMed  Google Scholar 

  40. Smolders J et al (2011) Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 311(1-2):44–49

    Article  CAS  PubMed  Google Scholar 

  41. Stein MS et al (2011) A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 77(17):1611–1618

    Article  CAS  PubMed  Google Scholar 

  42. Serpell MG, Notcutt W, Collin C (2013) Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 260(1):285–295

    Article  PubMed  Google Scholar 

  43. Kavia RB et al (2010) Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 16(11):1349–1359

    Article  CAS  PubMed  Google Scholar 

  44. Collin C et al (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32(5):451–459

    Article  CAS  PubMed  Google Scholar 

  45. Zajicek JP et al (2012) Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 83(11):1125–1132

    Article  PubMed  Google Scholar 

  46. Novotna A et al (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R))), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18(9):1122–1131

    Article  CAS  PubMed  Google Scholar 

  47. Notcutt W et al (2012) A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). Mult Scler 18(2):219–228

    Article  CAS  PubMed  Google Scholar 

  48. Langford RM et al (2013) A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 260(4):984–997

    Article  CAS  PubMed  Google Scholar 

  49. Broekmans T et al (2011) Effects of long-term resistance training and simultaneous electro-stimulation on muscle strength and functional mobility in multiple sclerosis. Mult Scler 17(4):468–477

    Article  PubMed  Google Scholar 

  50. Cakt BD et al (2010) Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. Am J Phys Med Rehabil 89(6):446–457

    Article  PubMed  Google Scholar 

  51. Collett J et al (2011) Exercise for multiple sclerosis: a single-blind randomized trial comparing three exercise intensities. Mult Scler 17(5):594–603

    Article  PubMed  Google Scholar 

  52. Conklyn D et al (2010) A home-based walking program using rhythmic auditory stimulation improves gait performance in patients with multiple sclerosis: a pilot study. Neurorehabil Neural Repair 24(9):835–842

    Article  PubMed  Google Scholar 

  53. Dodd KJ et al (2011) Progressive resistance training did not improve walking but can improve muscle performance, quality of life and fatigue in adults with multiple sclerosis: a randomized controlled trial. Mult Scler 17(11):1362–1374

    Article  CAS  PubMed  Google Scholar 

  54. Fimland MS et al (2010) Enhanced neural drive after maximal strength training in multiple sclerosis patients. Eur J Appl Physiol 110(2):435–443

    Article  PubMed  Google Scholar 

  55. Hebert JR et al (2011) Effects of vestibular rehabilitation on multiple sclerosis-related fatigue and upright postural control: a randomized controlled trial. Phys Ther 91(8):1166–1183

    Article  PubMed  Google Scholar 

  56. Prosperini L et al (2013) Home-based balance training using the Wii balance board: a randomized, crossover pilot study in multiple sclerosis. Neurorehabil Neural Repair 27(6):516–525

    Article  PubMed  Google Scholar 

  57. Prosperini L et al (2010) Visuo-proprioceptive training reduces risk of falls in patients with multiple sclerosis. Mult Scler 16(4):491–499

    Article  PubMed  Google Scholar 

  58. Motl RW et al (2011) Internet intervention for increasing physical activity in persons with multiple sclerosis. Mult Scler 17(1):116–128

    Article  PubMed  Google Scholar 

  59. Nilsagard YE, Forsberg AS, von Koch L (2013) Balance exercise for persons with multiple sclerosis using Wii games: a randomised, controlled multi-centre study. Mult Scler 19(2):209–216

    Article  PubMed  Google Scholar 

  60. Mori F et al (2010) Effects of anodal transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis. J Pain 11(5):436–442

    Article  PubMed  Google Scholar 

  61. Jurynczyk M et al (2010) Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol 68(5):593–601

    Article  CAS  PubMed  Google Scholar 

  62. Dalgas U et al (2010) Muscle fiber size increases following resistance training in multiple sclerosis. Mult Scler 16(11):1367–1376

    Article  CAS  PubMed  Google Scholar 

  63. Burton JM et al (2010) A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 74(23):1852–1859

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Filippi M et al (2012) Multiple sclerosis: effects of cognitive rehabilitation on structural and functional MR imaging measures--an explorative study. Radiology 262(3):932–940

    Article  PubMed  Google Scholar 

  65. Starck M et al (2010) Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol 257(3):322–327

    Article  PubMed  Google Scholar 

  66. Rice CM et al (2010) Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther 87(6):679–685

    Article  CAS  PubMed  Google Scholar 

  67. Velikonja O et al (2010) Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg 112(7):597–601

    Article  PubMed  Google Scholar 

  68. Mattioli F et al (2010) Efficacy and specificity of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis. J Neurol Sci 288(1-2):101–105

    Article  PubMed  Google Scholar 

  69. Naismith RT et al (2010) Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 74(23):1860–1867

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Jensen MP et al (2011) Effects of self-hypnosis training and cognitive restructuring on daily pain intensity and catastrophizing in individuals with multiple sclerosis and chronic pain. Int J Clin Exp Hypn 59(1):45–63

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Neuromodulation, Center of Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, USA

    Tarek Nafee, Rodrigo Watanabe & Felipe Fregni

  2. Spaulding Research Institute, Spaulding Rehabilitation Hospital, Harvard Medical School, Charlestown, MA, USA

    Felipe Fregni

Authors
  1. Tarek Nafee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodrigo Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Felipe Fregni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felipe Fregni .

Editor information

Editors and Affiliations

  1. Laboratory of Neuromodulation, Center of Clinical Research Learning, Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Felipe Fregni

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Nafee, T., Watanabe, R., Fregni, F. (2018). Multiple Sclerosis. In: Fregni, F. (eds) Clinical Trials in Neurology. Neuromethods, vol 138. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7880-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7880-9_8

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7879-3

  • Online ISBN: 978-1-4939-7880-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation